mProX™ Human ICOS Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;Rat T cells

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Immunology Research

Related Diseases

Immunodeficiency, Common Variable, 1; Common Variable Immunodeficiency

Gene ID

Human:29851

UniProt ID

Human:Q9Y6W8

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

ICOS (inducible T-cell co-stimulator) has various applications in different fields of research. In a study published in JCI Insight, researchers found that human HLA-DR+CD27+ regulatory T cells have enhanced antigen-specific suppressive function, which could be beneficial for the treatment of autoimmune diseases and graft rejection. Another study published in Prog Urol focused on the profile and immune environment of upper tract urothelial carcinoma. The researchers explored the immune infiltrate of UTUC and the expression of immune checkpoints and co-stimulatory molecules on tumor cells and lymphocytes. In Animal Model Exp Med, the expression and prognosis of ICOS and its ligand in Chinese lung adenocarcinoma patients were investigated. The study found that ICOS/ICOSL might be associated with the prognosis of lung cancer and could be potential therapeutic targets. In Allergy Asthma Clin Immunol, the immunological responses in SARS-CoV-2 and HIV co-infection were compared to SARS-CoV-2 mono-infection. The study highlighted the interplay between the two viruses and its implications for risk-mitigation approaches for HIV-infected individuals. Lastly, in Blood, researchers studied the role of Epstein-Barr virus (EBV) encoded EBNA2 in B-cell lymphoma. They found that EBNA2 downregulates ICOSL by inducing miR-24, which could contribute to immune evasion by EBV in lymphomas. Overall, these studies demonstrate the diverse applications of ICOS in understanding immune responses, cancer immunotherapy, and viral infections.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human ICOS Stable Cell Line (S01YF-1023-PY181). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Morgan Johnson (Verified Customer)

What is the significance of ICOS in T cell activation? Nov 17 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

ICOS is a critical co-stimulatory molecule that plays a significant role in T cell activation and function. It enhances T cell responses and is involved in the regulation of immune responses, particularly in cancer and autoimmune diseases. Nov 17 2021

chat Casey Smith (Verified Customer)

How does ICOS influence cancer immunotherapy? Dec 17 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

ICOS has emerged as a potential target in cancer immunotherapy. Its expression on T cells can be indicative of tumor-reactive T cells, and targeting ICOS can enhance the efficacy of immunotherapies, especially in combination with other checkpoint inhibitors like PD-1. Dec 17 2022

Published Data

Fig.1 The effectiveness of siRNA-mediated knockdown of ICOS was assessed through flow cytometry analysis in vitro.

The assessment of ICOS knockdown through siRNA was evaluated via flow cytometry in both in vitro settings. The upper right corners of each dot plot display the proportions of ICOS+CD4+ cells. These findings are representative of four separate experiments, including unactivated T cells (a), activated T cells (b), cells transfected with pRNAT-U6.1/Neo (c), cells transfected with pRNAT-U6.1/Neo-ICOS (d), and rat cells treated with pyrogen-free sterile water.

Ref: Hou, Yongsheng, et al. "Down-regulation of inducible co-stimulator (ICOS) by intravitreal injection of small interfering RNA (siRNA) plasmid suppresses ongoing experimental autoimmune uveoretinitis in rats." Graefe's Archive for Clinical and Experimental Ophthalmology 247 (2009): 755-765.

Pubmed: 19125271

DOI: 10.1007/s00417-008-1023-0

Research Highlights

Zhan, Xiao-Kai. et al. "Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients." Animal models and experimental medicine, 2023.
Immunotherapy is now the most rapidly adopted treatment approach for lung cancer, resulting in enhanced survival rates. One potential target for cancer immunotherapy is the inducible T-cell co-stimulator (ICOS), which can bind with its ligand, inducible T-cell co-stimulator and its ligand (ICOSL), to reverse immunosuppression and improve immune response. This presents a promising avenue for improving the effectiveness of immunotherapy in treating lung cancer.
Zhan, Xiao-Kai. et al. "Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients." Animal models and experimental medicine, 2023.
Pubmed: 37850501 DOI: 10.1002/ame2.12355

Shahbaz, Shima. et al. "Immunological responses in SARS-CoV-2 and HIV co-infection versus SARS-CoV-2 mono-infection: case report of the interplay between SARS-CoV-2 and HIV." Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2023.
There is currently an urgent need to gain a deeper understanding of the interrelation between SARS-CoV-2 and HIV. This understanding will greatly contribute to creating effective risk-mitigation strategies for individuals living with HIV. By exploring the connection between these two viruses, researchers and healthcare professionals can devise informed plans to reduce the risk of infection for HIV-positive individuals. Therefore, it is crucial to prioritize the study of the interplay between SARS-CoV-2 and HIV.
Shahbaz, Shima. et al. "Immunological responses in SARS-CoV-2 and HIV co-infection versus SARS-CoV-2 mono-infection: case report of the interplay between SARS-CoV-2 and HIV." Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2023.
Pubmed: 37848967 DOI: 10.1186/s13223-023-00846-8